Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Kardigan Q3 2026 Results: Net Loss of $58.6M, Loss Narrows

Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-58.6-60.2
Net income-58.6-60.2
EPS (diluted, $ a share)$-0.64$-4.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: KARD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Kardigan, Inc.: key numbers

Share price
$12.85Close, Nov 16
Market cap
$1.2B
Shares outstanding
93.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Kardigan, Inc.

All →
7:02 AM ET 8-K
Financial Results

Kardigan Financial Results

Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.

Term
Q3 2026

“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”

Tassos Gianakakos, co-founder, chief executive officer and board chair
4:07 PM ET 8-K
Business Update

Kardigan Business Update

Kardigan, Inc. has completed enrollment for its Phase 2b KATALYST-AV trial evaluating ataciguat in patients with aortic stenosis. The company also updated its trial protocol to assess the primary endpoint of aortic valve calcium at week 48 instead of earlier, based on real-world data analysis of disease progression. Topline data from the trial is now expected in the second half of 2027.

8:02 AM ET 8-K
Leadership Change

Kardigan Leadership Change

Kardigan, Inc. appointed Kristin Reinke, currently Vice President of Finance at Google, to its Board of Directors and as chair of the Audit Committee. Simultaneously, founding board member Doug Giordano resigned from the Board and Audit Committee. Ms. Reinke will receive an initial stock option grant valued at $650,000 as part of her appointment.

Counterparty
Kristin Reinke

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.